OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
Increasing molecular diversity is creating a need for the reinvention of process development and control strategies.
A thorough knowledge of both the upstream and downstream processes is required to ensure effective removal of residual impurities in biopharmaceuticals.
Pharma companies set goals and adopt more sustainable alternatives.
Learning from early market failures, the biopharma industry has worked to improve the fate of antibody drug conjugates.
Experts reveal how to identify the “right” biochemical, the process of sourcing biochemicals, sourcing challenges, and what industry professionals should know about the space.
Industry experts discuss best practices for certificates of analysis.
Various advances in contamination control are being utilized to reduce the chance pollutants contaminate a drug product.
December 02, 2022
The complete online database of ACS Reagent Chemicals is now available.
The design of viral clearance studies must keep pace with the quickly evolving biologic drugs industry.
December 01, 2022
Catalent has completed the expansion of its clinical supply facility located in Shanghai, China.
Results from Eisai and Biogen’s Alzheimer's treatment, lecanemab, indicated significantly slowed cognitive decline in patients relative to placebo.
Merck will use BigHat’s AI/machine learning-enabled platform to design candidates for up to three drug discovery programs.
mRNA may not be a train we necessarily all need to get onboard immediately, but we should know where the central train station is located, and what it connects us to.
Science news can be just so weird, or weirdly useful, that everything else recedes as we ponder whether it is true and what consequences it might bring.
November 30, 2022
The agreement will see Immutep and Merck KGaA, Darmstadt, Germany jointly fund the INSIGHT-005 study.
AstraZeneca inked a deal worth up to $320 million to purchase Neogene Therapeutics, a biotech start-up focused on T-cell receptor therapies.
Aptamer’s new 18,000 ft² facility will expand the company's capacity to deliver novel binders for bioprocessing, diagnostic, and drug development.
Etihad Cargo is one of the only airlines to hold IATA CEIV Pharma certification globally.
November 29, 2022
The decision to move forward in Phase III development stems from the threat of resistance to current malaria treatment growth.